公开(公告)号：US10294217B2

公开(公告)日：2019-05-21

申请号：US15758313

申请日：2016-07-19

Applicant: Suven Life Sciences Limited

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Abdul Rasheed Mohammed ,  Ramkumar Subramanian ,  Vijay Sidram Benade ,  Gopinadh Bhyrapuneni ,  Venkateswarlu Jasti

IPC: A61P25/28 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D417/06 ,  C07D417/14

Abstract: The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor. (Formula I)(I)

公开(公告)号：US20180244655A1

公开(公告)日：2018-08-30

申请号：US15758313

申请日：2016-07-19

Applicant: Suven Life Sciences Limited

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Abdul Rasheed Mohammed ,  Ramkumar Subramanian ,  Vijay Sidram Benade ,  Gopinadh Bhyrapuneni ,  Venkateswarlu Jasti

IPC: C07D403/06 ,  C07D401/06 ,  C07D417/06 ,  C07D401/14 ,  C07D401/12 ,  C07D417/14 ,  A61P25/28

CPC classification number: C07D403/06 ,  A61P25/28 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D417/06 ,  C07D417/14

Abstract: The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor. (Formula I) (I)

公开(公告)号：US09951045B2

公开(公告)日：2018-04-24

申请号：US15104521

申请日：2014-02-24

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Abdul Rasheed Mohammed ,  Anil Karbhari Shinde ,  Shankar Reddy Gagginapally ,  Venkateswarlu Jasti

IPC: C07D401/12 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D403/12

CPC classification number: C07D401/12 ,  C07D403/12 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14

Abstract: The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxy-tryptamine 4 (5-HT4) receptor agonists.

公开(公告)号：US12156871B2

公开(公告)日：2024-12-03

申请号：US16766112

申请日：2018-11-21

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Abdul Rasheed Mohammed ,  Rajesh Kumar Badange ,  Raghava Choudary Palacharla ,  Venkateswarlu Jasti

IPC: A61P25/28 ,  A61K31/13 ,  A61K31/27 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/445 ,  A61K31/473 ,  A61K31/55 ,  C07D471/04

Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the methods of preparation, pharmaceutical composition, combinations and the use of compound formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.

公开(公告)号：US09802896B2

公开(公告)日：2017-10-31

申请号：US15504210

申请日：2014-10-20

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Ramasastri Kambhampati ,  Venkateswarlu Jasti

IPC: C07D211/46

CPC classification number: C07D211/46 ,  C07D413/12

Abstract: The present, invention relates to a process for large scale production of N-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride of formula (I).

公开(公告)号：US11278530B2

公开(公告)日：2022-03-22

申请号：US16755864

申请日：2018-10-26

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Abdul Rasheed Mohammed ,  Anil Karbhari Shinde ,  Shankar Reddy Gagginapally ,  Durga Malleshwari Kancharla ,  Santosh Kumar Pandey ,  Renny Abraham ,  Venkateswarlu Jasti

IPC: A61K31/437 ,  A61P25/28 ,  A61K31/13 ,  A61K31/27 ,  A61K31/4155 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/445 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/538 ,  A61K31/55 ,  C07D215/48 ,  C07D235/04 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D405/14 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).

公开(公告)号：US11116764B2

公开(公告)日：2021-09-14

申请号：US16097458

申请日：2016-08-03

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Pradeep Jayarajan ,  Gopinadh Bhyrapuneni ,  Ramasastri Kambhampati ,  Venkateswarlu Jasti

IPC: A61K31/496 ,  A61K31/13

Abstract: The present invention relates to pure 5-HT6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The invention further relates to the pharmaceutical composition containing the said combination.

公开(公告)号：US09957257B2

公开(公告)日：2018-05-01

申请号：US15549663

申请日：2016-01-07

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Abdul Rasheed Mohammed ,  Sangram Keshari Saraf ,  Narsimha Bogaraju ,  Ramkumar Subramanian ,  Pradeep Jayarajan ,  Gopinadh Bhyrapuneni ,  Venkateswarlu Jasti

IPC: C07D405/12 ,  C07D405/14

CPC classification number: C07D405/12 ,  C07D405/14

Abstract: The present invention relates to compounds of formula (I), including their stereoisomers and pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-hydroxytryptamine 4 (5-HT4) receptor.

公开(公告)号：US09790211B2

公开(公告)日：2017-10-17

申请号：US14777925

申请日：2013-10-18

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Venkateswarlu Jasti

IPC: C07D401/12 ,  C07D405/14 ,  A61K31/4709 ,  G01N33/558 ,  G01N33/574

CPC classification number: C07D405/14 ,  C07D401/12 ,  G01N33/558 ,  G01N33/57426 ,  G01N2333/82 ,  G01N2800/52

Abstract: The present invention relates to novel quinoline compounds of formula (I), and their pharmaceutically acceptable salts and process for their preparation. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptor agonists.

公开(公告)号：US11622967B2

公开(公告)日：2023-04-11

申请号：US17059429

申请日：2018-08-01

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Vijay Sidram Benade ,  Saivishal Daripelli ,  Pradeep Jayarajan ,  Jyothsna Ravula ,  Venkateswarlu Jasti

IPC: A61K31/5377 ,  A61P25/00

Abstract: The present invention provides new methods of treatment for narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder by administering a therapeutically effect amount of histamine-3 receptor (H3R) inverse agonist, N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.